{"title":"冠心病的抗血小板治疗。","authors":"W H Frishman","doi":"10.1080/21548331.1982.11702306","DOIUrl":null,"url":null,"abstract":"Perhaps no recent development in cardiology has aroused so much interest and controversy as the role of platelet-aggregation inhibitors in the prevention of reinfarction and sudden death in patients with heart disease. Clinical trials of aspirin and other antiplatelet agents are reviewed. Despite their equivocal results, a pragmatic approach to antithrombotic prophylaxis is suggested.","PeriodicalId":79221,"journal":{"name":"Hospital practice (Hospital ed.)","volume":"17 5","pages":"73-86"},"PeriodicalIF":0.0000,"publicationDate":"1982-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1080/21548331.1982.11702306","citationCount":"20","resultStr":"{\"title\":\"Antiplatelet therapy in coronary heart disease.\",\"authors\":\"W H Frishman\",\"doi\":\"10.1080/21548331.1982.11702306\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Perhaps no recent development in cardiology has aroused so much interest and controversy as the role of platelet-aggregation inhibitors in the prevention of reinfarction and sudden death in patients with heart disease. Clinical trials of aspirin and other antiplatelet agents are reviewed. Despite their equivocal results, a pragmatic approach to antithrombotic prophylaxis is suggested.\",\"PeriodicalId\":79221,\"journal\":{\"name\":\"Hospital practice (Hospital ed.)\",\"volume\":\"17 5\",\"pages\":\"73-86\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"1982-05-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://sci-hub-pdf.com/10.1080/21548331.1982.11702306\",\"citationCount\":\"20\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Hospital practice (Hospital ed.)\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1080/21548331.1982.11702306\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Hospital practice (Hospital ed.)","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1080/21548331.1982.11702306","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
Perhaps no recent development in cardiology has aroused so much interest and controversy as the role of platelet-aggregation inhibitors in the prevention of reinfarction and sudden death in patients with heart disease. Clinical trials of aspirin and other antiplatelet agents are reviewed. Despite their equivocal results, a pragmatic approach to antithrombotic prophylaxis is suggested.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
